Fundraising FoxCaixa Capital Risc
Corporate VCBarcelona · Seed–Growth · 10 people tracked
Find your way into Caixa Capital Risc
Sign up to see every warm intro you have to Caixa Capital Risc
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Caixa Capital Risc team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Criteria Capital Risc, the venture capital manager of CriteriaCaixa, backs innovative companies in early stages and actively supports their development. It operates two specialized funds: Criteria Venture Tech, focused on deep tech with emphasis on artificial intelligence, cybersecurity, and software and data infrastructure; and Criteria Bio Ventures, focused on biotechnology and health, supporting the development of innovative therapies and scientifically grounded projects from early to growth stages. With over two decades of experience and a broad network of national and international co-investors, the firm maintains a diversified portfolio, emphasizing value creation and strategic support for entrepreneurial teams.
Source: firm website, verified Nov 8, 2026.
Team · 10 people
from public directories
David Sola is Director of Finance & Operations at Enline, a B2B deep-tech company developing software and digital twins for power grids. He oversees financial planning, reporting, cash management, operations, people processes, fundraising, corporate development, investor relations, and governance. Prior to joining Enline, he spent over a decade in venture capital, leading Seed and Series A investments in European B2B software and deep-tech companies and serving on multiple boards.
Albert Morro is a Principal at Criteria Venture Tech, where he invests between $1M and $10M in founders developing artificial intelligence, infrastructure, and deep technology solutions. He previously built and exited two companies: Nanoboost, a neuropharmacology company acquired by Laboratories Rubio, and Reby, a micromobility platform that reached $15M in annual revenue across 19 European cities before its acquisition by House of Lithium. Earlier in his career, he worked at HP on scaling the company's 3D printing division.
Sebastián Chiavenna is a Principal at Criteria Bio Ventures with eighteen years of experience across scientific, commercial, and operational functions in the life sciences sector. His background includes roles as a Scientific Marketing Manager in precision medicine, Medical Advisor covering oncology and cardiology biotechnology, Head of Project Development responsible for portfolio selection and lifecycle management, and Corporate Marketing Manager leading brand strategy for hospital-based products. He holds a PhD in Molecular Biology.
Víctor Cardoner is Head of the Structured Products and Derivatives desk at Santander Private Banking International. He has over 20 years of experience across capital markets, corporate banking, technology consulting, investing, and internet businesses. He has worked in Barcelona, Madrid, Paris, London, New York, and Lausanne.
What they invest in
from 8 of 10 portfolio companiesBiotech ×5Healthtech ×3Deep Tech ×2Longevity ×2Marketplaces ×2Medical Devices ×2AI & Machine Learning ×1Consumer ×1
HQs:Spain×3United States×1
Investments · 10 tracked
founders shown can be your intro pathBy year:2025 · 12024 · 12023 · 22022 · 15 dated
AbolerIS Pharma develops therapeutic approaches that regulate the immune system by inducing immune tolerance while preserving useful immune responses, targeting inflammatory, autoimmune, and degenerative diseases.
BiotechHealthtech
Ignacio Anegon(Co-founder, Senior Consultant & SAB Member)inCarole Guillonneau(Co-founder & Head of Research)inFrançois-Xavier Hubert(Co-founder, Past President & Board Member)
Co-investorsCriteria Bio VenturesNewton BiocapitalSound BioventuresSambrinvestWallonie Entreprendre
Arthex Biotech develops antisense RNA compounds to treat diseases with unmet medical needs.
AI & Machine LearningBiotechMedical Devices
Beatriz Llamusí(Chief Scientific Officer & Co-Founder)in
Co-investorsHadean VenturesSound BioventuresBpifranceColumbus Venture PartnersAdBio partnersInvivo Capital Partners
flowww is management software for clinics and centers in the beauty, aesthetic medicine, health, and wellness sectors, offering digital medical records with e-signatures, appointment booking, stock traceability, automated marketing, and real-time analytics.
Digital HealthSaaSWellness & Fitness
Co-investorsSwanlaab Venture Factory
Glovo is an on-demand delivery app that lets users order food from restaurants as well as groceries and goods from supermarkets, shops, pharmacies, and florists in their city.
FoodTechLogistics & Supply ChainMarketplacesBarcelona, ES
Oscar Pierre(Founder)Sacha Michaud(Founder)
Co-investorsBlue LionBlue Lion GlobalBonsai Partners SGEIC, SACriteria Venture TechDirlangoEntrée Capital+11 more
Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.
BiotechDeep TechHealthtechMedical DevicesMataró, ES
Marc Martinell(Co-Founder & Chief Executive Officer)in
Co-investorsChiesi VenturesCriteria Bio VenturesFund+Invivo Capital PartnersKurma PartnersRoche Venture Fund+7 more
NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.
BiotechHealthtechLongevity
Neil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inClaus Sundgreen(Chief Medical Officer)inPaul Thompson(CDO)in
BoardJonathan Savidge(Independent Non Executive Chair)
Co-investorsBrandon CapitalCriteria Bio VenturesNovartis Venture FundSV Health InvestorsBritish Business BankBrandon Capital Partners+4 more
Tolerance Bio develops therapeutics targeting the thymus—the regulator of immune tolerance—to preserve, restore, and manipulate its function and extend health span.
BiotechDeep TechLongevityPhiladelphia, US
Francisco Leon(Executive Officer, Director)inPhilip Ball(Executive Officer, Director)Justin Vogel(Executive Officer, Director)in
BoardDamia Tormo Carulla(Director)Pablo Cironi(Director)inRobert Goldstein(Director)
Co-investorsBioAdvanceColumbus Venture PartnersCriteria Bio VenturesBen Franklin Technology Partners
Wallapop is a mobile marketplace app that enables users to buy and sell items with other nearby users in their local community.
ConsumerMarketplaces
Agustín Gómez(Founder)inAgustin Gomez(Founder)Gerard Olivé(Founder)Miguel Vicente(Founder)Rob Cassedy (CEO)(Founder)
Co-investorsAccelBonsai Partners SGEIC, SACometaCriteria Venture TechFJ LabsGarapa+9 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Adaptam TherapeuticsCornerJob
Portfolio news
latest coverage across their companies
Tolerance Bio · biobuzz.io · Jul 13, 2026
Frequently asked questions
- How many investments has Caixa Capital Risc made?
- Caixa Capital Risc has 10 tracked investments, including 1 dated in the last 24 months.
- What stage does Caixa Capital Risc invest at?
- Caixa Capital Risc invests at the Seed, Series A, Series C, Growth stages.
- What sectors does Caixa Capital Risc focus on?
- Caixa Capital Risc focuses on AI & Machine Learning, Biotech, Cloud Computing, Cybersecurity, Data & Infrastructure, Deep Tech, Healthtech, HR Tech, Logistics & Supply Chain, Marketplaces.
- Where is Caixa Capital Risc located?
- Caixa Capital Risc is headquartered in Barcelona, ES.
Co-investors · 2
Swanlaab is a venture capital firm that invests in innovative, technology-driven companies, helping entrepreneurs with capital, know-how and structured methodologies to scale and expand internationally.
Armilar Venture Partners is an early-stage venture capital firm backing technology teams working to solve major societal problems.
Firms observed investing alongside Caixa Capital Risc, from public investor directories. Shared companies are the overlap with Caixa Capital Risc's recorded portfolio.